SCHEMBL4842646

SCHEMBL4842646

O=Cc1ccc(OCc2cnc(Cl)s2)cc1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.71
CYP2C9 P11712 1/20 0.71
CYP2C19 P33261 1/20 0.71
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
L3MBTL1 Q9Y468 5/20 0.63
TDP1 Q9NUW8 1/20 0.63
MAPT P10636 2/20 0.62
LMNA P02545 3/20 0.61
RAB9A P51151 2/20 0.61
POLB P06746 1/20 0.61
ATM Q13315 1/20 0.61
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.49
PTGES2 Q9H7Z7 1/20 0.47
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273137 0.84 MAOA (0.55) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL15380249 0.81 CYP1A2 (0.77) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL12585035 0.80 MEN1 (0.76) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL3778262 0.79 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL22315220 0.77 CYP1A2 (0.71) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4008435 0.77 CYP1A2 (0.70) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL14564274 0.77 KDM4E (1.00) RAB9APOLBKDM4E
SCHEMBL27821451 0.76 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL6974312 0.74 ALDH1A1 (0.51) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL28366278 0.74 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
EP-1539759-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016611-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 CYP1A2 1343/4885CYP2C9 2451/4885CYP2C19 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.